Current available therapies and future directions in the treatment of malignant gliomas

The prognosis of patients diagnosed with malignant glioma (MG) remains poor. However, recent advances in neuro-oncology allowing a better understanding of this particular disease have allowed the development of new therapeutics. Many molecular genetic and signal transduction pathway targets have bee...

Descripción completa

Detalles Bibliográficos
Autores principales: Desjardins, Annick, Reardon, David A, Vredenburgh, James J
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726053/
https://www.ncbi.nlm.nih.gov/pubmed/19707392
_version_ 1782170558456135680
author Desjardins, Annick
Reardon, David A
Vredenburgh, James J
author_facet Desjardins, Annick
Reardon, David A
Vredenburgh, James J
author_sort Desjardins, Annick
collection PubMed
description The prognosis of patients diagnosed with malignant glioma (MG) remains poor. However, recent advances in neuro-oncology allowing a better understanding of this particular disease have allowed the development of new therapeutics. Many molecular genetic and signal transduction pathway targets have been identified that are now being investigated. Novel locoregional treatments, as well as strategies to improve regional delivery, are being evaluated. Studies of combinations of these approaches are also underway. In this review, we will discuss the current and future therapies under evaluation for the treatment of malignant gliomas.
format Text
id pubmed-2726053
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-27260532009-08-25 Current available therapies and future directions in the treatment of malignant gliomas Desjardins, Annick Reardon, David A Vredenburgh, James J Biologics Review The prognosis of patients diagnosed with malignant glioma (MG) remains poor. However, recent advances in neuro-oncology allowing a better understanding of this particular disease have allowed the development of new therapeutics. Many molecular genetic and signal transduction pathway targets have been identified that are now being investigated. Novel locoregional treatments, as well as strategies to improve regional delivery, are being evaluated. Studies of combinations of these approaches are also underway. In this review, we will discuss the current and future therapies under evaluation for the treatment of malignant gliomas. Dove Medical Press 2009 2009-07-13 /pmc/articles/PMC2726053/ /pubmed/19707392 Text en © 2009 Desjardins et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Desjardins, Annick
Reardon, David A
Vredenburgh, James J
Current available therapies and future directions in the treatment of malignant gliomas
title Current available therapies and future directions in the treatment of malignant gliomas
title_full Current available therapies and future directions in the treatment of malignant gliomas
title_fullStr Current available therapies and future directions in the treatment of malignant gliomas
title_full_unstemmed Current available therapies and future directions in the treatment of malignant gliomas
title_short Current available therapies and future directions in the treatment of malignant gliomas
title_sort current available therapies and future directions in the treatment of malignant gliomas
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726053/
https://www.ncbi.nlm.nih.gov/pubmed/19707392
work_keys_str_mv AT desjardinsannick currentavailabletherapiesandfuturedirectionsinthetreatmentofmalignantgliomas
AT reardondavida currentavailabletherapiesandfuturedirectionsinthetreatmentofmalignantgliomas
AT vredenburghjamesj currentavailabletherapiesandfuturedirectionsinthetreatmentofmalignantgliomas

Ejemplares similares